Organon & Co. OGN

Organon Canada, a global healthcare company, today announces the approval and availability of NDUVRA® (tapinarof cream), 1%, for the topical treatment of moderate to severe atopic dermatitis in adult and pediatric patients 2 years of age and older.

Why MIUDELLA’s FDA review matters for Organon stock Organon (OGN) just picked up fresh attention after the FDA accepted a supplemental application to extend use of MIUDELLA, a copper IUD that Organon licensed globally earlier this year. The device is already indicated for pregnancy prevention for up to 3 years, with an extended duration review underway and commercial availability targeted for late 2026. For investors watching Organon stock, this product sits squarely in the women’s health...

Organon (NYSE: OGN) received FDA acceptance to review a supplemental New Drug Application for its hormone free contraceptive device MIUDELLA. The company entered an exclusive global licensing agreement for MIUDELLA, aiming to expand access to hormone free contraception across markets. Organon plans commercial availability of MIUDELLA as a longer duration contraceptive option, subject to regulatory review outcomes and launch execution. Beyond the MIUDELLA sNDA review and new global license,...

PhaseV, a leader in machine learning for clinical development, today announced the appointment of Klaus Beck, MD, PhD, PhD, former Chief Medical Officer of Organon, and Avi Kulkarni, PhD, MBA, CEO of InoRx, to its Scientific Advisory Board.

JERSEY CITY, N.J., September 14, 2026--Organon announces FDA accepts MIUDELLA® sNDA for review, seeking to extend approved hormone-free IUD use from 3 to 6 years in the U.S.

Investors hammered Cooper Companies on Thursday after the medtech's fiscal third-quarter sales lagged Wall Street's expectations.

Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

VANCOUVER, BC / ACCESS Newswire / September 2, 2026 / . ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the acquisition of the Toro de Oro and El Gigante gold projects in Southwest Utah, USA.

Jeannette Jager, CEO Arletta Pharma Solutions Jeannette Jager van Dijk, appointed Chief Executive Officer of Arletta Pharma Solutions, effective September 1, 2026. www.arlettapharmasolutions.com Global women’s health executive to lead Arletta in its development strategy focused on advancing Lybrido™’s (sildenafil/testosterone) Phase 2 MONARCH study following positive FDA correspondence Effective September 1, 2026Over 30 years of successful global commercial, marketing and product development lea

The first national investigator-led study focused on Canadian women’s experiences of menopause and the menopausal transition is now inviting participants, in partnership with GreenShield and supported by a charitable grant from OrganonTORONTO, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Women’s Health Collective Canada (WHCC) and the Partnership for Women’s Health Research Canada (PWHR), in partnership with GreenShield and supported by a charitable grant from Organon, have launched the Researching Informa

VANCOUVER, BC / ACCESS Newswire / August 13, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSXV:OGN)(OTCQX:OGNNF) is pleased to announce the voting results for its Annual General Meeting (the "Meeting") of shareholders held August 13, ...

Legal operations and legal department leaders from Mastercard, Meta, Google, Uber, General Motors, U.S. Bank, Capital One and more will help shape the future of outside counsel managementNEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Priori, the legal technology company modernizing outside counsel management and hiring, today announced the members of its 2026–2027 Client Advisory Board (CAB), a group of senior legal operations and legal department leaders who provide strategic guidance on the compa

JERSEY CITY, N.J., August 11, 2026--HCPs, healthcare settings and pharmacies can begin REMS certification for Organon’s hormone-free copper IUD, MIUDELLA, ahead of upcoming launch.

VANCOUVER, BC / ACCESS Newswire / August 5, 2026 / Orogen Royalties Inc. ("Orogen" or the "Company") (TSX.V:OGN) (OTCQX:OGNNF) is pleased to announce the acquisition of the Two Peaks CRD and skarn project in Arizona, USA. Two Peaks Project Highlights ...

JERSEY CITY, N.J., July 31, 2026--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that the company’s Board of Directors declared a quarterly dividend of $0.02 for each issued and outstanding share of the company's common stock. The dividend is payable on September 10, 2026, to stockholders of record at the close of business on August 14, 2026.